**PDE1A polymorphism contributes to the susceptibility of nephrolithiasis**

Zhenxing Yang¹, Tao Zhou¹, Bishao Sun¹, Qingqing Wang¹, Xingyou Dong¹, Xiaoyan Hu¹, Jiangfan Zhong¹,³, Bo Song² and Longkun Li¹,³*

**Abstract**

**Background:** Previous studies have confirmed a family risk of nephrolithiasis (NL), but only 15% of all cases are associated with an identified monogenic factor. In clinical practice, our group encountered a patient with NL combined with cystic kidney disease that had 3 affected family members. No known mutations association with NL was detected in this family, and thus further investigation of the molecular cause of NL was deemed to be necessary.

**Results:** Quality analysis from the sequencing stage showed a more than 80-fold average depth and 95% coverage for each sample, and six mutations within six genes were chosen as candidate variants for further validation. Genotyping of rs182089527 in the phosphodiesterase 1A (PDE1A) gene in the validation cohort indicated that the alternative allele was present in 15 patients with heterozygosity and in 1 patient with homozygosity, and exhibited significant enrichment in NL patients (Fisher’s exact test, adjusted \( p = 0.0042 \)) and kidney cystic patients (Fisher’s exact test, adjusted \( p = 0.067 \)) compared to controls. In addition, function analysis displayed a significant decrease in the protein and mRNA expression levels resulting from the rs182089527 mutant sequence compared with the wild-type sequence. Moreover, patients with this mutation displayed a high level of creatinine and urea in urinalysis.

**Conclusions:** Our study provides genetic evidence that the rs182089527 mutation in PDE1A is involved in the development of NL and kidney cysts, which should help to improve personalized medicine for diagnosis and treatment.

**Keywords:** PDE1A, Nephrolithiasis, Polymorphism

**Background**

Nephrolithiasis (NL), also known as kidney stones, is a common disease associated with major morbidity because of colicky pain, the necessity of surgical procedures, and even acute renal failure [1]. The estimated lifetime prevalence of NL is about 1–15% worldwide, which varies according to age, gender, race, and geographic location. In China, the overall prevalence rate was estimated to be 4.0% (4.8% in men and 3.0% in women), and the prevalence was different between northern (4.1%) and southern regions (4.0%) [2]. Both genetic and environmental factors contribute to the risk of NL. In a genetic epidemiology follow-up investigation of a cohort of 37,999 male participants, the relative risk of the incidence of stone formation in men with a positive family history was 2.75 (95% confidence interval = 2.19–3.12) [3]. A twin study in Vietnam indicated that the proband concordance rate in monozygotic twins (32.4%) was significantly greater than the rate in dizygotic twins (17.3%), and the estimated heritability of the risk for NL was 56%.

The genetic cause of NL is complicated, ranging from the rare monogenic to the more common polygenic forms. To date, at least 30 genes have been reported to be associated with Mendelian forms of NL or nephrocalcinosis by autosomal-recessive, autosomal-dominant, or X-linked
transmission [4, 5]. Several renal calcium stone-related disorders are known to be monogenic, such as Dent disease (Online Mendelian Inheritance in Man [OMIM 300009]), Bartter’s syndrome, idiopathic hypercalciuria, primary distal renal tubular acidosis, hypophosphatemic rickets with hypercalciuria, familial hypomagnesemia with hypercalciuria and nephrocalcinosis, primary hyperoxaluria, cystinuria, renal hypouricemia, and hypocitraturic hypercalciuria [6], but only about 15% of 272 genetically unrelated individuals were shown to have single-gene disease which have mentioned above [7]. With the development of microarray technology, genome-wide association studies have also been employed to investigate the susceptibility genes of NL. One such study conducted by Gudmar et al. [8] identified common, synonymous variants in the CLDN14 gene that were associated with kidney stones, and homozygous carriers of the single nucleotide polymorphism (SNP) rs219780[C] in CLDN14 were estimated to have a 1.64-times greater risk of developing the disease compared to non-carriers. Another study conducted in Japan found three novel loci for NL and revealed the association of SNP rs11746443 (upstream of the SLC34A1 gene) with the reduction of estimated glomerular filtration rate [9]. Although dozens of susceptibility genes have been reported, in-depth analysis of the monogenic causes of NL is still necessary.

With the advent of next-generation sequencing, the mutation analysis of Mendelian genes has not only become technically available but is also cost-effective. In clinical practice, our group encountered a family affected by NL (Fig. 1), with four family members affected. Proband DNA samples were collected and sequenced initially, but no known association mutation of NL was detected.

In addition, renal cysts are extremely common and are present in more than one third of NL patients older than 50 years. More importantly, NL shows a common complication of kidney cyst development. Therefore, to further explore the potential causal genes, we employed whole-exome sequencing technology of blood samples from 10 family members (4 affected and 6 unaffected) and 2307 validation samples (including 993 NL patients and 1314 controls, 328 kidney cystic patients and 622 controls) to investigate the causal mutations, and postulated that NL may be a monogenic disease. Following functional validation was conducted using RT-PCR and western blot.

Methods
Sample collection
Proband and nephrolithiasis family description
A elder man presented with post-polio syndrome of right foot claudication, 20 years history of renal calculi, repeated bilateral back pain, urgent micturition, hematuria and dysuria. The patient suffered from hypertension almost 10 years, admitted oral antihypertensive drugs, and also complained with intermittent voiding stones in urine 3 times, but was not treated. He had noticed with aggravation of back pain and voiding stones in urine again 1 month ago, which make them admitted to our Urology Department. Physical examination revealed a temperature of 36.3 °C, pulse of 102, blood pressure (BP) of 109/88 mmHg, left flank tenderness and a palpable left kidney but was otherwise normal. Laboratory testing indicated that creatinine concentration was 89.9 umol/L, the serum calcium was 2.26 mmol/L, uric acid was 357 umol/L, serum phosphorus was 1.06 mmol/L, and serum magnesium was 0.78 mmol/L. The serum electrolytes were within normal limits. Urinalysis showed specific gravity of 1.02, PH 6.5, no protein, and 6 to 10 white blood cells and red blood cells (RBCs) per high-power field without casts or crystals. Abdominal ultrasound showed multiple cystic dark areas with the maximum diameter of 2.2 cm, clear boundaries and regular morphology. Ultrasonography and
computed tomography (CT) of left kidney demonstrated hydronephrosis, no marked parenchymal atrophy, and multiple stones in the renal pelvis. There was a cystic dark area, diameter of 1.1 cm, in right kidney with regular morphology and clear boundary (Additional file 1: Figure S1). The patient has endured family history of nephrolithiasis (Fig. 1).

**Cohort samples**

Nine hundred ninety three cases of nephrolithiasis (NL) and 1314 controls were obtained from the Second Affiliated Hospital of Third Military Medical University during the period of 2013–2016. Diagnostic evaluations were performed separately in person using standardized criteria for diagnosing nephrolithiasis. Two independent raters collected family history from the proband, each participating parent, and a nursing sister recorded pedigree information during the clinical interview. In addition, 328 cases patients with simple cyst and 622 matched (1:2) controls were recruited for PDE1A genotype analysis. All of the cases were diagnosed by spiral computed tomography (CT), ultrasonography or X ray. Control inclusion criteria: ① Screen for a lifetime absence of NL or cyst using CT, ultrasonography or X ray. ② Excluded significant complication disease of NL or cyst. This study was conducted with the approval of the ethics committee of Third Military Medical University. Whether the participants had the capacity to consent was evaluated by the following criteria: Firstly, patients have the ability to understand and reasoning; Secondly, patients have the ability to make rational decisions. All participants gave written informed consent; parental consent for children who were younger than 18 years old was obtained.

**DNA and RNA extraction and quality controls**

Genomic DNA was extracted from peripheral blood cells using TIANamp Blood DNA Kit (TIANGEN BIOTECH, BEIJING) following as the manufacturer’s instructions. Total RNA was extracted from whole blood with MagMAX™ for Stabilized Blood Tubes RNA Isolation Kit following the manufacturer’s instructions. Quality control of DNA or RNA were conducted by Agarose gel electrophoresis and λDNA-Hind III digest band (Additional file 1: Figure S2).

**Captured library construction, Clustering & Sequencing**

Each sequenced sample was prepared according to the Illumina protocols. Briefly, onemicrogram of genomic DNA was fragmented by nebulization, the fragmented DNA isrepaired, an ‘A’ is ligated to the 3’ end, Illumina adapters are then ligated to the fragments, and the sample was size selected aiming for a 350–400 base pair product. The size selected product was PCR amplified, and the final product was validated using the Agilent Bioanalyzer. Two steps of hybridization and wash were needed for construction. PCR was used in order to amplify the enriched DNA library for sequencing. PCR was performed with the same PCR primer cocktail used in TruSeq DNA Sample Preparation. Axiq Technologies performs procedures for quality control analysis on the sample library and quantification of the DNA library templates. Illumina utilizes a unique “bridged” amplification reaction that occurs on the surface of the flow cell. A flow cell containing millions of unique clusters was loaded into the HiSeq 2004 for automated cycles of extension and imaging. Following cluster generation, 151 nt paired-end sequencing was performed using the standard Illumina protocols.

**Quality control for sequencing results and variants calling**

Quality control of raw data was conducted by FastQc software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were mapped to a custom hg19 build using Burrows-Wheeler Alignment tool (BWA). The duplicate reads were flagged using Picard-tools (http://broadinstitute.github.io/picard/). GATK IndelRealigner module was used to realign reads around insertion/deletion (Indel) sites. Individual sequence data (in BAM format) was preprocessed as whole NGS community suggests which mainly include local Indel realignment, PCR duplicates removal and base quality recalibration. Read qualities were recalibrated using GATK Table Recalibration. GATK unified Genotyper module was then used to call variants (both SNVs and Indels) from multiple samples simultaneously, which create a single Variant Call Format (VCF) file. Raw read data were visualized using the Integrative Genome Viewer (IGV). Individual level quality control was conducted on raw and clean variant to make sure avoiding false positive variants. A suite of per-individual metrics, which included the total number of alternate alleles, dbSNP coverage (build137), and Transition/Transversion (Ti/Tv) ratio, and variant quality recalibration (VQSR) were calculated. From available exome data, we extracted common variants and estimated per-individual heterozygosity (~inbreeding), pairwise relatedness, and sex-check using PLINK (Additional file 2: Table S1). Variants quality control was conducted by software KGGSeq (http://statgenpro.psychiatry.hku.hk/limx/ kggseq/ doc/UserManual.html), which were carefully designed to filter and prioritize gene variants in exome sequencing of rare Mendelian and common complex disorder.

Candidate mutation from the next generation sequencing were tested using standard Sanger sequencing on an ABI 3730xl DNA Analyzer to validate the reality, by designing
custom primers (Sigma) based on ~200 bp of genomic sequence flanking each variant (Additional file 1: Figure S3).

Variance quality control and candidate gene filtering
Variants were kept if (1) the minimum overall sequencing quality scores ≥ 50 (−seq-qual 50) and the minimum overall mapping quality score ≥ 20 (−seq-mq 20); (2) The minimal genotyping quality per genotype ≥ 30 (−gty-quality 30) and the minimal read depth per genotype ≥ 30 (−gty-qual 30); (3) The fraction of the reads carrying alternative allele ≤ 5% at a reference-allele homozygous genotype (−gty-ref 0.05), the fraction of the reads carrying alternative allele ≥ 25% at a heterozygous genotype (−gty-het 0.25), and the fraction of the reads carrying alternative allele ≥ 75% at an alternative-allele homozygous genotype (−gty-alt 0.75); (4) Minimal observed number of non-missing genotypes in all samples as 50 (−min-obs 50).

Candidate variants were kept if (1) mutation present in patients with nephrolithiasis, but not in family members. (2) Nonsynonymous; All mutations were annotation by Annovar, we ignored synonymous variants because nucleotide substitution of these kind variants does not change amino acid. (3) Predict damaging; All of nonsynonymous variants that met any of the following criteria were considered potentially damaging: frameshift, nonsense, stoploss, stopgain, splicing and missense mutation with Polyphen score ≥ 1.0 and/or SIFT p ≤ 0.05 and/or Grantham score ≥ 100 and/or phyloP score ≥ 2.0. (4) SNP or In/Del within a gene, which have been proved with the cause of nephrolithiasis or related pathway in previous study.

Genotyping
Six SNPs were chosen for further validation which based on the prediction scores, minor allele frequency (MAF) and function annotation (Additional file 2: Table S2). The SNP genotyping was performed using an improved multiplex ligation detection reaction (iMLDR) technique or TaqMan, which was newly developed by Genesky Biotechnologies, Inc. (Shanghai, China). We designed primers and probes for TaqMan genotyping assays for SNP rs182089527. Each genomic DNA sample (20 ng) was amplified with TaqMan universal PCR master mix reagent (Applied Biosystems, Foster City, CA) combined with the specific TaqMan SNP genotyping assay mixture, corresponding to the SNP to be genotyped. The iMLDR technique was applied for genotyping remaining SNPs which follow the instruction.

The sequencing of PDE1A designed primers as following:
Upper primer: TGACCTCTCACATATGCTGCTGT. Lower primer: TTGGTGAGGCTCTCTTTGATCA.

Functional studies
Construction of mutation expression plasmid
Blood samples were collected from all family members. RNA was extracted and was converted into complementary DNA (cDNA) using a Reverse Transcription System Kit (Invitrogen, Carlsbad, CA, USA). Wild-type and mutant-type of p.M1R in PDE1A9 were harvested from 6 unaffected members and 4 affected patients.

cDNAs were PCR-amplified with forward primer and reverse primer (5'-TACCGGACTCTAGATCCTGAGCGC CACCAGGGGCAAAAAGATAAACAAAC-3' and 3'-GATCCCCGGCCCGGTACCGGTCTGATGAATAAAC TCACACCTTCTG-5'). Human wild-type and mutant PDE1A9 insertion into the GV320 vector (SHANGHAI GENECHROM CO., LTD.). The viruses were collected on Day 3 after the transfection and were concentrated by ultracentrifugation. Transport plasmid with human wild-type and mutant PDE1A9 constructs were transiently or stably transfected into Tubular epithelial cells (ATCC, Manassas VA, USA; CCL-93). All constructs were verified by sequencing.

Cell culture
All the tubular epithelial cell lines were provided by prof. Jing Zhang and her student Yi Gong (Department of Nephrology, The Third Military University) and cultured in DMEM supplemented with 10% fetal bovine-serum, streptomycin (100 mg/ml) and penicillin (100 U/ml). Cells were serum deprived for 6 h before treatment with transport plasmid and then cultured in DMEM containing 0.5% fetal bovine serum (conditioned medium).

Western blot
Protein was extracted from cultured tubular epithelial cell lines after washed with PBS and lysed in RIPA buffer (Beyotime, Shanghai, China). Protein concentration was measured using the RCDC method (BIO-RAD, USA). Total protein extracts of 50 μg were separated using 8–10% SDS-PAGE gels (Beyotime, Shanghai, China) and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, USA). After blocked with 5% BSA at room temperature for 2 h and the membranes were incubated with primary antibodies against PDE1A9 at 4 °C overnight followed by the secondary antibodies. Proteins were visualized using ECL (Millipore, Bradford, MA, USA) and detected using Image Quant LAS-4000 (FujiFilm, Tokyo, Japan) BioImaging System.

RT-PCR
Cultured tubular epithelial cells were lysed on the ice for 20 min. cDNAs were synthesized by Sensiscript RT Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The primers was the same as above.
description. The thermocycling program consisted of 94 °C for 1 min, 60 °C for 30 s and 72 °C for 1 min (40 cycles). The PCR products were visualized using 2% agarose gel electrophoresis followed by GoldView (SBS Genetech Co., Beijing, China) staining.

**Statistical analysis**
Clinical characteristics are presented as means ± SD. The chi-squared test or Fisher’s exact test with Bonferroni correction was used for the analysis of contingency tables depending on the sample size. Monte Carlo simulation was employed to calculate the difference between the NL patients with the rs182089527 mutation and healthy control group. All statistical analyses were conducted using R software (http://www.R-project.org/).

**Results**
**Sequencing**
We enriched exonic sequences from the 10 family members using the Illumina TruSeq Exome Enrichment system for targeted exome capture, and Illumina paired-end sequencing was performed. On average, 61.09 Gb of mappable sequence data per individual were obtained after exome enrichment, targeting ~74.86 Mb from the exons and their flanking regions. The paired-end reads were aligned to the reference genome (hg19 build) using the Burrows-Wheeler Aligner (BWA) [10]; 98.5% of the reads were correctly aligned to the reference genome. The median read depth was 82×, which was higher than the estimated depth (33×) for highly accurate downstream heterozygous variant calling. In addition, 94.37% of the captured target exomes were covered by high-quality genotype calls at least 20 times to ensure proper detection sensitivity [11] (Additional file 2: Table S1). Overall, we covered about 2.39% of the genome, a fraction corresponding to the National Center for Biotechnology Information Consensus Coding Sequences database. After prioritization of the candidate variants list, six SNPs within six genes (PDE1A, CERK1, MAN2B2, CYPIA2, NAGLU and NFATC1) were chosen for further validation (Additional file 2: Table S2).

**Clinical characterization and genotyping**
The gender and age distributions did not differ significantly between either 993 NL cases and 1314 controls, or 328 kidney cystic patients and 622 controls. There was a significant difference in the frequency of SNP rs182089527 in the phosphodiesterase 1A gene (PDE1A) between the NL patients and controls (Fisher’s exact test, $p = 0.0003$, Bonferroni correction $p = 0.0042$) (Table 1). Data obtained from the 1000Genome database showed that the minor allele of rs182089527 is C, with a frequency of 0.26%, indicating that only 13 of 2500 individuals carry this mutation [12]. In the current investigation, 19 of the 2307 total samples showed the rs182089526 variant allele C with a minor allele frequency (MAF) of 0.43%, which is slightly higher than that of the global population in the 1000 Genomes Project database, with significantly greater enrichment in the case group (chi-squared test, $p = 0.0012$, odds ratio [OR] =3.31). More importantly, the rs182089527 distribution also showed a trend of difference between kidney cyst patients and healthy controls for both the allele (Fisher’s exact test, $p = 0.0048$, adjusted $p = 0.067$) and genotype (Fisher’s exact test, $p = 0.0049$, adjusted $p = 0.068$) comparisons.

**Functional and expression analyses in tubular epithelial cells**
To determine whether the rs182089527 mutation results in a change in the expression level of PDE1A isoform 5, we measured the protein and mRNA expression levels between tubular epithelial cells injected with the wild type (WT) and rs182089527 mutant sequence. Western blot and reverse transcription-polymerase chain reaction (RT-PCR) results indicated a significant decrease ($P < 0.001$) in the protein and mRNA expression levels of cells transfected with the rs182089527 mutant sequence compared with those carrying the WT type sequence (Additional file 1: Figure S4). The data were derived from a minimum of 40 tubular epithelial cells with 3 biological replications per experiment.

**Genotype-phenotype correlations**
A total of 19 patients with NL displayed the C allele mutation in the PDE1A gene. Only two of 19 patients were subjected to stone component analysis, revealing calcium oxalate stones. Urinalysis indicated that all of 19 patients had high level of creatinine (Monte Carlo simulation, $p = 0.0012$) and urea (Monte Carlo simulation, $p = 0.016$). The pH level differed slightly between the cases and controls in the urine (lower in cases, $p = 0.048$) and blood (slightly higher in cases, $p = 0.089$) (Fig. 2). No other laboratory findings showed difference in these subgroups (Additional file 1: Figure S5).

**Discussion**
Initial analysis of a pedigree family affected by NL revealed a loss-of-function mutation in the PDE1A gene that contributed to the susceptibility of NL. This mutation was also detected in a second cohort of patients suffering from NL, at a frequency of 1.61%. Transfection of a plasmid with cDNA expressing the rs182089527 mutation in a tubular epithelial cell line revealed the complete loss of function of PDE1A isoform 5 (also known as PDE1A9).

To our knowledge, this is the first study to investigate the genetic cause of cystic kidney disease. Previous studies suggested an association of genetic factors with autosomal-
dominant transmission, but were lacking in detailed data. In the current study, we detected the rs182089527 mutation in 
PDE1A in 5 patients suffering from cystic kidney disease. The 
PDE1A gene, located within chromosome 2q32.1, includes 23 exons and encodes 9 isoforms of PDE1A through alternative splicing [13]. PDE1A belongs to the family of cyclic nucleotide phosphodiesterases (PDEs) that play an important role in signal transduction by regulating the intracellular cyclic nucleotide concentrations through hydrolysis of cAMP and/or cGMP to their respective nucleoside 5’ monophosphates. The PDE1A gene encodes Ca^{2+}/calmodulin-dependent PDEs that are activated by calmodulin in the presence of calcium, leading to increased hydrolysis of both cAMP and cGMP [14]. The rs182089527 mutation identified in the current investigation only influenced the function and expression of PDE1A isoform 5 (PDE1A9), which is mainly expressed in the brain tissue [15]. Although we did not conduct further functional analysis on PDE1A9, its expression level has been reported to be lower than that of other isoforms [13].

| rs182089527 Nephrolithiasis (N = 993) | Normal (N = 1314) | P value | OR | 95% CI | Adjust P |
|--------------------------------------|------------------|--------|----|--------|----------|
| AA/AC/CC 977/15/1                       | 1310/3/0        | 0.0003 |    |        | 0.0042   |
| A/C 1969/17                            | 2623/3          | 0.00015 | 7.55 | [2.21, 25.8] | 0.0021   |
| Cystic (N = 328) Normal (N = 622)    |                  |        |    |        |          |
| AA/AC/CC 323/5/0                       | 622/0/0         | 0.0048 |    |        | 0.0672   |
| A/C 651/5                              | 1244/0          | 0.0049 | ∞  | [1.74, ∞] | 0.0686   |

*OR Odds Ratio
*Bonferroni correction for original P value

**Fig. 2** Randomly choose 19 values of clinical experimental test in patients from 894 values of clinical experimental test in normal controls got an empirical distribution of average values for different clinical experiment lab test. The red line denoted the average values from 19 samples with rs182089527 mutation. CREA, creatinine
We propose three possible mechanisms contributing to the apparent association of PDE1A9 with NL. First, PDE1A9 is the main digestive enzyme for cGMP, and thus deprivation of PDE1A9 leads to an increase of cGMP levels, which can influence the secretion of H₂O, Na⁺, Cl−, and HCO₃⁻ through the renin secretion pathway. More importantly, the change of the acidic environment in tubular epithelial cells may influence the formation of stones in the kidney. This hypothesis is somewhat supported by the present genotype–phenotype correlation analysis, which showed that the levels of creatinine and urea were increased in the urine of patients suffering from NL compared with those of control samples. Second, in addition to PDEase_I_N and the HDc motif, PDE1A9 also has Zn²⁺- and Mg²⁺-binding sites, and thus depletion of PDE1A9 can lead to enrichment of Zn²⁺ and Mg²⁺ in the cytoplasm, which could in turn contribute to NL development by damaging cell function or influencing the balance of ions. Third, the complete lack of PDE1A9 expression in tubular epithelial cells may lead to cystogenesis, resulting in the dysfunction of tubular cells and contributing to the progress of NL. This assumption is based on the following observations: (1) knockout of PDE1A changes cAMP signaling in renal development, thereby progressing cystogenesis [16]; (2) in the present study, patients with the rs182089527 mutation showed cystic changes in the kidney and liver, as well as hypertension, typical clinical characteristics of polycystic kidney disease.

In the current study, the MAF of rs182089527 was 0.43%, which was higher than the frequency of 0.26% in data from the 1000 Genomes database, and was also more frequently detected in the NL patients (1.61%). Moreover, the MAF of rs182089527 was found to be close to zero in Europeans and African Americans [17], which may explain the difference in the prevalence of NL between different ethnic groups. However, further larger cohort data are needed to clarify this findings.

The monogenic nature of NL suggested by the present results has practical implications that could help to facilitate personalized treatment. However, there are several questions that remain based on the current investigation. First, the potential mechanism by which the rs182089527 mutation leads to disease requires further research. In particular, the distribution and function of PDE1A isoform 5 is unclear, which will be important information to help explain the progress of NL. Second, the relationships among the rs182089527 mutation, NL, and cyst development need to be clarified. Previous case reports have pointed to the coexistence of NL and renal cysts [18]. It is possible that the rs182089527 mutation leads to a cystic change, and then causes the development of NL. Although the potential mechanism underlying the association between NL and the rs182089527 mutation requires further investigation in prospective trials, our results highlight the complex and heterogeneous nature of NL, which may facilitate personalized treatment as well as prenatal screening.

Conclusion
Our study provided genetic evidence that the rs182089527 mutation in PDE1A may be involved in the development of NL. Our clinical and molecular findings may contribute to gaining a better understanding of the mechanism underlying NL as well as the relationship between NL and cysts.

Additional files

**Additional file 1: Figure S1-S5.** Auxiliary clinical examination and experiment data. (DOCX 624 kb)

**Additional file 2: Table S1-S2.** Sequence quality statistical and candidate gene list. (DOCX 18 kb)

**Abbreviations**

NL: Nephrolithiasis; PDE1A: Phosphodiesterase 1A; SNP: Single nucleotide polymorphism

**Acknowledgements**

Special thanks give prof. Jing Zhang and her student Yi Gong (Department of Nephrology, The Third Military University) to provide tubular epithelial cell lines for research. We are also grateful for Majorbio Pharm Technology Co., Ltd., Shanghai to do whole-exome sequencing for us.

**Funding**

Current work was supported by the National Natural Science Foundation of China (81470398 and 81600588), and partly by the clinical research project key projects of Second Affiliated Hospital, Third Military Medical University (2015YLJ06).

**Availability of data and materials**

All related sequencing data was available at public database figshare (https://figshare.com/articles/PDE1A_polymorphism_contributes_to_the_susceptibility_of_nephrolithiasis/4564819).

**Authors’ contributions**

ZXY performed the sequencing and statistical analyses and manuscript preparing. Mr. TZ and BSS were responsible for the blood sample collection. XYD, QOW and XYH advised on the biological functional experiment. LKL, B5 and JFZ devised such research and also revised manuscript for publishing. All the authors read and approved the final manuscript.

**Ethics approval and consent to participate**

All experiments involving clinical patient samples were performed in accordance with a protocol approved by the Research Council and Animal Care and Use Committee of the Third Military Medical University, China. Whether the participants had the capacity to consent was evaluated by the following criteria: Firstly, patients have the ability to understand and reasoning; Secondly, patients have the ability to make rational decisions. All participants gave written informed consent; parental consent for children who were younger than 18 years old was obtained.

**Consent for publication**

Consent for publication was sought from the participants in this study.

**Competing interests**

All authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, People’s Republic of China. 2Department of Urology, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China. 3Ostrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.

Received: 29 June 2017 Accepted: 31 October 2017

References
1. Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):804–11.
2. Zeng Q, He Y. Age-specific prevalence of kidney stones in Chinese urban inhabitants. Urolithiasis. 2013;41(1):91–3.
3. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol. 1997;8(10):1568–73.
4. Stechman MJ, Loh NY, Thakker RV. Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N Y Acad Sci. 2007;1116:461–84.
5. Devuyst O, Pison Y. Genetics of hypercalciuric stone forming diseases. Kidney Int. 2007;72(9):1065–72.
6. Gambare G, Vezzoli G, Casari G, Rappoldi L, D’Angelo A, Borghi L. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. J Am Soc Nephrol: JASN. 2015;26(3):543–51.
7. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol: JASN. 2015;26(3):543–51.
8. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, Sulem P, Halldorsson BV, de Vegt F, d’Ancona FC, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009;41(8):926–30.
9. Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, Kamatani N, Kohri K, Chayama K, Kubo M. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. PLoS genetics. 2012;8:e1002541.
10. Li H, Durbin R. Fast and accurate short read alignment with burrows–wheeler transform. Bioinformatics. 2009;25(14):1754–60.
11. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456(7218):53–9.
12. Consortium GP. A global integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7242):56–65.
13. Ichikawa H, Yanaka N, Kanoh Y, Okumura K, Omori K. Human Ga2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization. Biochim Biophys Acta. 2001;1517(2):278–87.
14. Wang JH, Sharma RK, Mooibroek MJ. Calmodulin-stimulated cyclic nucleotide phosphodiesterases: Structure, Regulation Drug Action. 1990:219–59.
15. Snyder PB, Florio VA, Ferguson K, Loughney K. Isolation, expression and analysis of splice variants of a human Ga2+/calmodulin-stimulated phosphodiesterase PDE1A. Cell Signal. 1999;11(7):535–44.
16. Sussman CR, Ward CJ, Leightner AC, Smith JL, Agarwal R, Harris PC, Torres VE. Phosphodiesterase 1A modulates cystogenesis in zebrafish. J Am Soc Nephrol: JASN. 2014;25(10):2222–30.
17. Consortium GP. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.
18. Stapor K, Jeromin L, Wisniewski J, Sosnowski M. A case of coexistence of renal carcinoma with nephrolithiasis and adenoma in the renal cyst wall diagnosed at operation. Int Urol Nephrol. 1980;12(2):109–12.